SAN FRANCISCO — Direct Flow Medical Inc. (Santa Rosa, Calif.), a private company known for its development of transcatheter aortic valve replacement (TAVR) solutions, is going back to its roots to develop a platform to address mitral valve disease. In an exclusive interview with Medical Device Daily, during the 34th annual J.P. Morgan Healthcare conference, Direct Flow Medical CEO, Dan Lemaitre, said the company would debut the valve during the Heart Team 2nd Mitral Valve Meeting 2016, running Feb. 14 through 16 in Zurich.